Comparison of Cerebral Artery Pressure Gradient and Cerebral Blood Flow Measured by Arterial Spin Labeling

Xuanwu Hospital, Beijing25 enrolled

Overview

The goal of this observational study is to explore the ability of intravascular pressure gradients to identify hemodynamic disturbance in patients with intracranial atherosclerotic diseases (ICAS). The main questions that aim to answer are: * The correlation between intravascular pressure gradient and cerebral blood flow (CBF) * The threshold for intravascular pressure gradients to predict hemodynamic disturbance in ICAS Patients will undergo intravascular pressure measurement and arterial spin labeling (ASL) for CBF during pre- and post-operation respectively.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Stroke, Ischemic Intracranial Atherosclerosis

Interventions

Endovascular treatmentPROCEDURE

Patients treated with endovascular treatment, including balloon angioplasty alone and balloon angioplasty plus stenting.

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients aged 40 years or older. 2. Patients with transient ischemic attack (TIA) or nondisabling ischemic stroke caused by a focal ICAS lesion located in intracranial anterior circulation (vertebral artery, basilar artery or intracranial internal carotid artery and their major branches). 3. 50% to 99% stenosis (calculated by modified WASID method) of responsible arterial occlusion, confirmed by digital subtraction angiography (DSA). 4. Informed of the study protocol and objectives. Exclusion Criteria: 1. Non-atherosclerotic MCA stenosis 2. Combined with moderate or severe stenosis of other extracranial and intracranial arteries 3. Previous endovascular treatment or surgery for cerebrovascular diseases 4. Large cerebral infarction (more than 1/2 MCA perfusion area) 5. Combined with other neurological diseases, such as aneurysm, arteriovenous malformation, tumor, hydrocephalus, cerebral trauma, cerebral hemorrhage, multiple sclerosis, epilepsy and intracranial infection. 6. Vascular abnormality or stunting, resulting in the impossibility of endovascular intervention 7. Liver and kidney dysfunction, or severe allergy to the contrast agent 8. Severe coagulation dysfunction 9. Pregnancy or in the preparation for pregnancy 10. Patients who cannot tolerate or do not allow MR screening, including metal implanting and claustrophobia 11. Patients with severe dementia or mental disorders, who cannot cooperate with examination

Outcomes

Primary Outcomes

The relevance between intravascular pressure gradients and CBF

Patients will be divided into 2 groups according to whether they have hemodynamic disorders before operation and improve after operation. Fractional flow reserve (FFR) measurement will be analyzed in each group.

Time frame: Post-operation, an average of 3 days

Secondary Outcomes

The difference of ASL-CBF between pre- and post-operation

The mean cerebral blood flow (CBF) of ipsilateral region of interest (ROI) in two different layers will be recorded as CBF in MCA perfusion area of this side. Relative CBF (rCBF) is defined as the ratio of the affected side CBF to the contralateral CBF. When preoperative rCBF\<0.9 and postoperative rCBF≥0.9, the patient will be considered to have hemodynamic disorders and be improved post-operation.

Time frame: Baseline and Post-operation, an average of 3 days

The difference of FFR between pre- and post-operation

FFR measurement will be performed at rest by 0.014-inch pressure guide wires (C12008, Abbot St. Jude Medical, Minneapolis, MN, USA) designed for coronary diseases. The mean endovascular pressure of distal and proximal lesions will be measured and recorded as Pd and Pa, respectively. Pd/Pa and Pa-Pd will be calculated and recorded before and after endovascular treatment.

Time frame: Baseline and Post-operation, an average of 3 days

Any stroke or death in short term.

Time frame: 30±5 days

Procedure-related complications

Any complications, related to manometry and treatment, will be recorded including arterial dissection, arterial perforation, acute vascular occlusion and other adverse events.